No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LLY240524C680000
- 129.52
- 0.000.00%
15min DelayTrading May 24 13:26 ET
0.00High0.00Low
0.00Open129.52Pre Close0 Volume0 Open Interest680.00Strike Price0.00Turnover1334.58%IV-2.49%PremiumMay 24, 2024Expiry Date150.21Intrinsic Value100Multiplier-9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9870Delta0.0005Gamma6.41Leverage Ratio-75.8670Theta0.0002Rho6.33Eff Leverage0.0016Vega
Intraday
- 5D
- 1D
News
QurAlis Grants Lilly Exclusive Global License For QRL-204, A Precision Therapy That Restores UNC13A Function In ALS And FTD
QRL-204 is a splice-switching ASO generated through QurAlis' FlexASO Platform; represents Lilly's first program targeting UNC13A in ALS and FTDParties to also collaborate to leverage QurAlis' ALS and
Eli Lilly Granted Exclusive License to QurAlis Candidate for Neurodegenerative Diseases
Eli Lilly and Co's Options: A Look at What the Big Money Is Thinking
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and Co.Looking at options history for Eli Lilly and Co (NYSE:LLY) we detected 22 trades.If we consider the speci
The Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon
While Dow Inc. futures are slightly down, IT and high tech stocks are being bought. Gamestop is rapidly rising in after-hours trading = US Stocks.
While Dow futures are slightly down in the US stock index futures market, buying is expanding in IT and high-tech stocks, causing the S&P 500 and NASDAQ 100 to rise today.
Structure Therapeutics' Stock Jumps on Weight-loss-pill Trial Results
By Eleanor Laise GLP-1 drugs in pill form could improve the medications' accessibility and affordability, analysts say Structure Therapeutics Inc.'s American depositary receipts (GPCR) gained more t
Comments
$Viking Therapeutics(VKTX.US$ yes company very cheap considering how much total market valuations the other three companies have achieved from just GLP-1 market (Obesity) contribution alone
$Eli Lilly and Co(LLY.US$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US$ 50-100 Billion if not wrong
$Amgen(AMGN.US$ 20+ Billion on no data yet
$Eli Lilly and Co(LLY.US$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US$ 50-100 Billion if not wrong
$Amgen(AMGN.US$ 20+ Billion on no data yet
1
1
In the last 18 months, $Eli Lilly and Co(LLY.US$ 's mkt cap has moved from $340B to roughly $770B today, there has to be close to $300-$400B attributed to GLP-1, agree? If close to being true, this just simply points to dramatic undervaluation of $Viking Therapeutics(VKTX.US$ with only a $7B mkt cap and what looks like a better GLP-1 franchise. Big pharma wastes a lot of money on stupid deals but this one at $15B is a lay-up. I think a BO happens any day and at a huge premium. Anyone smart enough to buy...
3
Nvidia delighted investors when it announced a 10-for-1 stock split last week. The move may be the start of a trend, as several prominent tech companies trade at prices high enough to tip the scales toward similar splits, according to a note from Bank of America.
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
72
2
$Hims & Hers Health(HIMS.US$ has added GLP-1 weight-loss injections to its portfolio of products.
The injections will have the same active ingredient as $Novo-Nordisk A/S(NVO.US$ ’s Ozempic and Wegovy.
HIMS stock is up by nearly 100% year-to-date.
Hims & Hers added that it would provide branded GLP-1 injections once supply catches up with demand. In the upcoming months, Hims & Hers will work towards providing access to compounded tirzepatide, whic...
The injections will have the same active ingredient as $Novo-Nordisk A/S(NVO.US$ ’s Ozempic and Wegovy.
HIMS stock is up by nearly 100% year-to-date.
Hims & Hers added that it would provide branded GLP-1 injections once supply catches up with demand. In the upcoming months, Hims & Hers will work towards providing access to compounded tirzepatide, whic...
4
Read more
communicative Axolot : that's cute did you know you can get all the glp1 drugs on Facebook for about 50$ a vial with out a script from hundreds of research grade suppliers?